Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
zongertinib
Sort By
Newest First
Sign in
1 / 1
1 / 1
FDA
Boehringer's Zongertinib ReceivesFDA Priority Review for the Treatment of HER2 (ERBB2)- NSCLC
Boehringer Ingelheim Pharmaceuticals, Inc.
PR-02-25-NI-21
Feb 20, 2025
